Corcept Therapeutics Incorporated (CORT)

25.45 +0.18 (+0.71%) At close: 04:00PM EST

Corcept Therapeutics Incorporated

149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270
https://www.corcept.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 299

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Joseph K. Belanoff M.D.	Co-Founder, President, CEO & Director	1.82M	19.31M	1957
Mr. Atabak Mokari	CFO & Treasurer	760.75k	N/A	1977
Dr. Hazel Hunt Ph.D.	Chief Scientific Officer	895.16k	1.75M	1960
Mr. Sean Maduck	President of Corcept Endocrinology	823.42k	3.37M	1977
Mr. Gary Charles Robb	Chief Business Officer & Secretary	963k	4.82M	1963
Mr. Joseph Douglas Lyon	Chief Accounting Officer	N/A	N/A	1979
Ms. Amy Flood	Chief Human Resources & Communications Officer	N/A	N/A	N/A
Dr. William Guyer Pharm.D.	Chief Development Officer	N/A	N/A	1968
Ms. Monica Tellado	President of Emerging Markets	N/A	N/A	1973

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Corporate governance

Corcept Therapeutics Incorporated’s ISS governance QualityScore as of 28 November 2023 is 6. The pillar scores are Audit: 4; Board: 4; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.